AU2019306543A1 - Antibodies against campylobacter species - Google Patents

Antibodies against campylobacter species Download PDF

Info

Publication number
AU2019306543A1
AU2019306543A1 AU2019306543A AU2019306543A AU2019306543A1 AU 2019306543 A1 AU2019306543 A1 AU 2019306543A1 AU 2019306543 A AU2019306543 A AU 2019306543A AU 2019306543 A AU2019306543 A AU 2019306543A AU 2019306543 A1 AU2019306543 A1 AU 2019306543A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
campylobacter
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019306543A
Other languages
English (en)
Inventor
Fabio Benigni
Davide Corti
Fabio Grassi
Lisa PERRUZZA
Matteo PIZZUTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Humabs Biomed SA
Original Assignee
Inst Res Biomedicine
Institute for Research in Biomedicine IRB
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine, Institute for Research in Biomedicine IRB, Humabs Biomed SA filed Critical Inst Res Biomedicine
Publication of AU2019306543A1 publication Critical patent/AU2019306543A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019306543A 2018-07-17 2019-07-16 Antibodies against campylobacter species Pending AU2019306543A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699573P 2018-07-17 2018-07-17
US62/699,573 2018-07-17
PCT/US2019/042070 WO2020018584A2 (en) 2018-07-17 2019-07-16 Antibodies against campylobacter species

Publications (1)

Publication Number Publication Date
AU2019306543A1 true AU2019306543A1 (en) 2021-01-28

Family

ID=67480448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019306543A Pending AU2019306543A1 (en) 2018-07-17 2019-07-16 Antibodies against campylobacter species

Country Status (13)

Country Link
US (1) US12297258B2 (https=)
EP (1) EP3823727A2 (https=)
JP (2) JP2021530237A (https=)
KR (1) KR20210041557A (https=)
CN (1) CN112867541B (https=)
AU (1) AU2019306543A1 (https=)
BR (1) BR112021000772A2 (https=)
CA (1) CA3105222A1 (https=)
EA (1) EA202190194A1 (https=)
IL (1) IL280234A (https=)
MX (1) MX2021000268A (https=)
SG (1) SG11202013193XA (https=)
WO (1) WO2020018584A2 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
EP1676862B1 (en) 2003-09-24 2010-12-22 Kyowa Hakko Kirin Co., Ltd. Recombinant antibody against human insulin-like growth factor
JP2008501625A (ja) * 2003-11-21 2008-01-24 エース バイオサイエンシズ エー／エス 表在Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉポリペプチド
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
KR20150073211A (ko) 2012-10-24 2015-06-30 내셔날 리서치 카운실 오브 캐나다 항―캄필로박터 제주니 항체 및 그의 용도
JP5916946B2 (ja) 2013-03-11 2016-05-11 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法

Also Published As

Publication number Publication date
JP2024116266A (ja) 2024-08-27
CN112867541B (zh) 2024-08-30
CA3105222A1 (en) 2020-01-23
WO2020018584A3 (en) 2020-04-02
IL280234A (en) 2021-03-25
KR20210041557A (ko) 2021-04-15
US20210284718A1 (en) 2021-09-16
SG11202013193XA (en) 2021-02-25
EP3823727A2 (en) 2021-05-26
WO2020018584A2 (en) 2020-01-23
CN112867541A (zh) 2021-05-28
JP2021530237A (ja) 2021-11-11
BR112021000772A2 (pt) 2021-04-13
US12297258B2 (en) 2025-05-13
MX2021000268A (es) 2021-06-08
EA202190194A1 (ru) 2021-04-16

Similar Documents

Publication Publication Date Title
US11479599B2 (en) Antibodies against SARS-CoV-2 and methods of using the same
CA3166627A1 (en) Antibodies against sars-cov-2 and methods of using the same
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
CN104955847A (zh) HIV-1 Env结合抗体、融合蛋白及其使用方法
CA3067416A1 (en) Use of anti-fam19a5 antibodies for treating cancers
TW202207983A (zh) 用於sars-cov-2感染的抗體療法
WO2023064841A1 (en) Antibodies for use against sars-cov-2
CA3194162A1 (en) Antibodies against sars-cov-2
CN117460833A (zh) 表达抗ror1/抗cd3双特异性抗体的溶瘤病毒
US12297258B2 (en) Antibodies against Campylobacter species
US20220048988A1 (en) Cells expressing antibodies targeting human immunodeficiency virus and methods of using the same
EP4687973A1 (en) Combined antibodies against sarbecoviruses and uses thereof
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
JP2025522295A (ja) インフルエンザノイラミニダーゼに対する広域中和抗体
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法
HK40053364A (en) Antibodies against campylobacter species
US20240101648A1 (en) Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same
RU2832110C1 (ru) Поливалентная векторная вакцина hvt
WO2024086566A2 (en) Pan-sarbecovirus neutralizing antibodies and methods of use thereof
TW202210505A (zh) 抗sars-cov-2之抗體
WO2023039442A9 (en) Broadly neutralizing antibody combination therapies for sars-cov-2 infection
HK40102827A (zh) Dna编码的用於抵抗sars-cov-2的抗体